Eli Lilly and Company (NYSE:LLY) Shares Acquired by Herold Advisors Inc.

Herold Advisors Inc. raised its holdings in Eli Lilly and Company (NYSE:LLY) by 1.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 11,656 shares of the company’s stock after buying an additional 213 shares during the quarter. Eli Lilly and Company accounts for 2.4% of Herold Advisors Inc.’s investment portfolio, making the stock its 5th largest holding. Herold Advisors Inc.’s holdings in Eli Lilly and Company were worth $10,555,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Everpar Advisors LLC acquired a new position in Eli Lilly and Company during the fourth quarter worth $1,845,000. International Assets Investment Management LLC grew its stake in Eli Lilly and Company by 5.3% in the 4th quarter. International Assets Investment Management LLC now owns 12,597 shares of the company’s stock valued at $7,343,000 after purchasing an additional 632 shares during the period. AMJ Financial Wealth Management bought a new position in Eli Lilly and Company in the 4th quarter valued at $201,000. GUNN & Co INVESTMENT MANAGEMENT INC. increased its position in shares of Eli Lilly and Company by 124.7% during the 4th quarter. GUNN & Co INVESTMENT MANAGEMENT INC. now owns 1,438 shares of the company’s stock valued at $838,000 after purchasing an additional 798 shares during the last quarter. Finally, Marks Group Wealth Management Inc raised its stake in shares of Eli Lilly and Company by 28.8% during the 4th quarter. Marks Group Wealth Management Inc now owns 612 shares of the company’s stock worth $357,000 after purchasing an additional 137 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 2,052 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total value of $1,660,068.00. Following the transaction, the insider now owns 98,554,195 shares of the company’s stock, valued at $79,730,343,755. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, major shareholder Lilly Endowment Inc sold 2,052 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the completion of the transaction, the insider now owns 98,554,195 shares of the company’s stock, valued at $79,730,343,755. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Johna Norton sold 7,056 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the completion of the transaction, the executive vice president now owns 25,428 shares in the company, valued at $20,835,194.64. The disclosure for this sale can be found here. Insiders sold a total of 1,122,141 shares of company stock valued at $991,938,411 in the last three months. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY stock traded down $1.43 during trading hours on Friday, reaching $952.74. The stock had a trading volume of 2,063,309 shares, compared to its average volume of 3,096,351. The stock’s fifty day simple moving average is $886.32 and its 200 day simple moving average is $813.81. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a 12 month low of $516.57 and a 12 month high of $972.53. The firm has a market capitalization of $905.49 billion, a PE ratio of 140.32, a PEG ratio of 1.81 and a beta of 0.41.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.55%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on LLY. Guggenheim raised their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Berenberg Bank raised their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. BMO Capital Markets upped their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Jefferies Financial Group increased their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Finally, Wells Fargo & Company boosted their target price on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $956.88.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.